Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and Adjuvant Exemestane in Locally Advanced Breast Cancer
NCT00080613Phase 2Withdrawn
- Sponsor
- Robert H. Lurie Comprehensive Cancer Center
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of exemestane in breast cancer, sponsored by Robert H. Lurie Comprehensive Cancer Center. Primary endpoint: Clinical Response Rate. Status: withdrawn.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00080613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080613.